DERMAGO receives over 1.6 million euros in capital with Companisto

DERMAGO receives over 1.6 million euros in capital with Companisto

16. January 2024 0

Around 370 Companists pledged to invest in the manufacturer of prescription dermatologicals

The pharmaceutical startup DERMAGO recently successfully closed its financing round on the private investor network Companisto and secured a total of around EUR 1.6 million in capital. Around 370 Companists and co-investors participated. The startup manufactures and distributes prescription drugs in the field of dermatology.
DERMAGO promotes access to new dermatological drugs and thus provides high social added value. DERMAGO markets its prescription drugs for skin diseases such as acne, neurodermatitis and genital warts worldwide via a distribution network of renowned international pharmaceutical companies.
The DERMAGO Group is the parent company of the three pharmaceutical companies Aresus Pharma, DEGODE Pharma and Skin Care Pharma. All three companies were merged into a group structure in 2021 in order to exploit synergies in sales, development, quality management and administration. The parent company DERMAGO has already completed its second financing round with Companisto.
The team around founder Sven Schimansky-Wabra will receive capital with the successfully completed financing round, which will be used for the expansion of the product portfolio, the further development of the company’s own pharmaceutical laboratory and the expansion of international sales. In addition, the DERMAGO team has received valuable support from the network through the participation of around 370 investors. This will enable the team to benefit from extensive knowledge and diverse experience in the future.

“I am very pleased that, together with Companisto, we have been able to attract additional investors to support us in our growth strategy. Many thanks to our investors for their trust and to Companisto for their professional support during the financing round. We will use the new capital primarily to advance our clinical trial for our drug Veregen ® in the indication actinic keratosis,” says Sven Schimansky-Wabra, CEO of DERMAGO, about the successful investment round and the cooperation with Companisto.


DERMAGO GmbH is a service company that specializes in developing unique generic versions and originator products of prescription dermatological drugs that are eligible for reimbursement and independently bringing them through the pharmaceutical approval process.
DERMAGO GmbH’s services also include consulting activities, scientific assessments, the preparation of expert opinions and qualitative and quantitative studies, especially for dermatological pharmaceuticals. The development of analytical methods and procedures as well as services for the approval of pharmaceuticals are also part of the range of services.

About Companisto
Companisto is the market-leading private investor network in the D-A-CH region and has been a leading venture capital provider for startup investments for seven years in a row. To date, Companisto has committed around EUR 223.1 million in over 310 financing rounds. Since 2018, Companisto has expanded its network of currently 149,000 private investors with a digitally organized Business Angel Club. Around 2,100 business angels invest in the equity of companies via Companisto with investments starting at EUR 10,000. The investment process and investment management have been fully digitalized.

Further information can be found at,,

Contact person
Companisto GmbH | Köpenicker Str. 154 | 10997 Berlin

Keywords for press release:
Companisto, DERMAGO, startup, pharma startup, pharma startup,

Leave a Reply

Your email address will not be published. Required fields are marked *